🇺🇸 FDA
Patent

US 9717759

Modification of CXCR4 using engineered zinc finger proteins

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 9717759 (Modification of CXCR4 using engineered zinc finger proteins) held by Sangamo Therapeutics, Inc. expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K40/11, A61K40/46